Haemonetics Corp (HAE) · Aug 18, 2026 · Material agreement
CSL supply agreement — Non-exclusive agreement with no minimum purchase commitments
Haemonetics adds CSL as a plasma-collection customer for NexSys devices, but no purchase minimums or revenue estimate leave the payoff unresolved.
The agreement is strategically meaningful but not yet an earnings event. Haemonetics says CSL may transition part of its U.S. plasma-center network to NexSys PCS devices and related disposables, adding a potentially important customer relationship. 〔0〕
The financial upside is currently too vague to call a beat versus expectations. The agreement is non-exclusive, carries no minimum purchase commitments, and has no disclosed center count, rollout schedule, order volume, or revenue contribution. 〔1〕 That means investors cannot yet translate the headline into a reliable fiscal 2027 estimate.
Management is deliberately withholding a guidance change until adoption becomes measurable. Haemonetics is keeping fiscal 2027 guidance unchanged and plans to discuss the agreement's expected impact at its fiscal second-quarter earnings call in November 2026. 〔2〕
Net read: a modest strategic positive, but with limited near-term information value. The customer win broadens validation for NexSys and could create future recurring disposable revenue, but the lack of commitments makes the economics entirely contingent on CSL's eventual rollout and purchasing behavior. Until November's update, this is better viewed as potential upside rather than a quantified improvement to the outlook.
Fiscal Q2 earnings call, November 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!